Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hesham Abboud

Showing results (51-60 of 68) with videos related to

Pageof 7
Sort By:
Frontiers in Immunology|January 27, 2025
Switch from eculizumab to satralizumab in aquaporin 4 immunoglobulin G-seropositive neuromyelitis optica spectrum disorder: a case series reportHesham Abboud, Adnan Subei, Buse Sengul, et al.
Neurology|March 27, 2025
The Clinical Trial Landscape in Autoimmune Encephalitis: Challenges and OpportunitiesHesham Abboud, Stacey L Clardy, Divyanshu Dubey, et al.
Journal of the Neurological Sciences|November 15, 2025
Factors influencing timeliness of reporting results from multiple sclerosis related clinical trials to ClinicalTrials.govMark Cwajna, Abdelrahman M Hamouda, Nicholas Kendall, et al.
Movement Disorders Clinical Practice|October 27, 2018
Comprehensive, Multidisciplinary Deep Brain Stimulation Screening for Parkinson Patients: No Room for "Short Cuts"Hesham Abboud, Raja Mehanna, Andre Machado, et al.
Journal of the Neurological Sciences|January 8, 2022
Residual symptoms and long-term outcomes after all-cause autoimmune encephalitis in adultsHesham Abboud, Farren Briggs, Robin Buerki, et al.
Parkinsonism & Related Disorders|January 13, 2015
Impact of mild cognitive impairment on outcome following deep brain stimulation surgery for Parkinson's diseaseHesham Abboud, Darlene Floden, Nicolas R Thompson, et al.
Neurosurgery|August 22, 2019
Factors Associated With Postoperative Confusion and Prolonged Hospital Stay Following Deep Brain Stimulation Surgery for Parkinson DiseaseHesham Abboud, Gencer Genc, Saira Saad, et al.
Journal of Neuroimmunology|March 25, 2025
Satralizumab treatment in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder after rituximab treatment: A case seriesHesham Abboud, Brian Steingo, Diana Vargas, et al.
Parkinson'S Disease|August 31, 2017
Predictors of Functional and Quality of Life Outcomes following Deep Brain Stimulation Surgery in Parkinson's Disease Patients: Disease, Patient, and Surgical FactorsHesham Abboud, Gencer Genc, Nicolas R Thompson, et al.
Frontiers in Neurology|August 28, 2024
Innovation and optimization in autoimmune encephalitis trials: the design and rationale for the Phase 3, randomized study of satralizumab in patients with NMDAR-IgG-antibody-positive or LGI1-IgG-antibody-positive autoimmune encephalitis (CIELO)Soon-Tae Lee, Hesham Abboud, Sarosh R Irani, et al.
Pageof 7

Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
Frontiers in Immunology|January 27, 2025
Switch from eculizumab to satralizumab in aquaporin 4 immunoglobulin G-seropositive neuromyelitis optica spectrum disorder: a case series reportHesham Abboud, Adnan Subei, Buse Sengul, et al.
Neurology|March 27, 2025
The Clinical Trial Landscape in Autoimmune Encephalitis: Challenges and OpportunitiesHesham Abboud, Stacey L Clardy, Divyanshu Dubey, et al.
Journal of the Neurological Sciences|November 15, 2025
Factors influencing timeliness of reporting results from multiple sclerosis related clinical trials to ClinicalTrials.govMark Cwajna, Abdelrahman M Hamouda, Nicholas Kendall, et al.
Movement Disorders Clinical Practice|October 27, 2018
Comprehensive, Multidisciplinary Deep Brain Stimulation Screening for Parkinson Patients: No Room for "Short Cuts"Hesham Abboud, Raja Mehanna, Andre Machado, et al.
Journal of the Neurological Sciences|January 8, 2022
Residual symptoms and long-term outcomes after all-cause autoimmune encephalitis in adultsHesham Abboud, Farren Briggs, Robin Buerki, et al.
Parkinsonism & Related Disorders|January 13, 2015
Impact of mild cognitive impairment on outcome following deep brain stimulation surgery for Parkinson's diseaseHesham Abboud, Darlene Floden, Nicolas R Thompson, et al.
Neurosurgery|August 22, 2019
Factors Associated With Postoperative Confusion and Prolonged Hospital Stay Following Deep Brain Stimulation Surgery for Parkinson DiseaseHesham Abboud, Gencer Genc, Saira Saad, et al.
Journal of Neuroimmunology|March 25, 2025
Satralizumab treatment in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder after rituximab treatment: A case seriesHesham Abboud, Brian Steingo, Diana Vargas, et al.
Parkinson'S Disease|August 31, 2017
Predictors of Functional and Quality of Life Outcomes following Deep Brain Stimulation Surgery in Parkinson's Disease Patients: Disease, Patient, and Surgical FactorsHesham Abboud, Gencer Genc, Nicolas R Thompson, et al.
Frontiers in Neurology|August 28, 2024
Innovation and optimization in autoimmune encephalitis trials: the design and rationale for the Phase 3, randomized study of satralizumab in patients with NMDAR-IgG-antibody-positive or LGI1-IgG-antibody-positive autoimmune encephalitis (CIELO)Soon-Tae Lee, Hesham Abboud, Sarosh R Irani, et al.
Pageof 7